Immunotherapy Resistance in Small Cell Lung Cancer: Mechanisms and Therapeutic Vulnerabilities
In small cell lung cancer (SCLC), immune checkpoint inhibitors (ICIs) combined with platinum-based chemotherapy are standard first-line treatment for extensive-stage disease. However, durable disease control remains uncommon. This review examines lineage plasticity, epigenetic regulation, defective antigen presentation...